Suppr超能文献

肽硼酸蛋白酶体抑制剂硼替佐米的氧化去硼反应:活性氧在这种新型细胞色素P450反应中的作用。

Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.

作者信息

Labutti Jason, Parsons Ian, Huang Ron, Miwa Gerald, Gan Liang-Shang, Daniels J Scott

机构信息

Department of Drug Metabolism and Pharmacokinetics, Drug Safety and Disposition, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.

出版信息

Chem Res Toxicol. 2006 Apr;19(4):539-46. doi: 10.1021/tx050313d.

Abstract

Bortezomib (1) is a potent first-in-class dipeptidyl boronic acid proteasome inhibitor employed in the treatment of patients with relapsed multiple myeloma where the disease is refractory to conventional lines of therapy. The potency of 1 is owed primarily to the presence of the boronic acid moiety, one which is suited to establish a tetrahedral intermediate with the active site N-terminal threonine residue of the proteasome. Hence, deboronation of 1 represents a deactivation pathway for this chemotherapeutic agent. Deboronation of 1 affords a near equal mixture of diastereomeric carbinolamide metabolites (M1/M2) and represents the principal metabolic pathway observed in humans. In vitro results from human liver microsomes and human cDNA-expressed cytochrome P450 enzymes (P450) indicate a role for P450 in the deboronation of 1. Use of 18O-labeled oxygen under controlled atmospheres confirmed an oxidative mechanism in the P450-mediated deboronation of 1, as 18O was found incorporated in both M1 and M2. Chemically generated reactive oxygen species (ROS), such as those generated as byproducts during P450 catalysis, were also found to deboronate 1 resulting in the formation of M1 and M2. Known to undergo efficient redox cycling, P450 2E1 was found to catalyze the deboronation of 1 predominantly to the carbinolamide metabolites M1 and M2, as well as to a pair of peroxycarbinolamides, 2 and 3. The presence of superoxide dismutase (SOD) and catalase prevented the deboronation of 1, thus, supporting the involvement of ROS in the P450 2E1-catalyzed deboronation reaction. The presence of SOD and catalase also protected 1 against P450 3A4-catalyzed deboronation, albeit to a lesser extent. The remaining deboronation activity observed in the P450 3A4 reaction may suggest the involvement of the more conventional activated enzyme-oxidants previously described for P450. Our present findings indicate that the oxidase activity of P450 (i.e., formation of ROS) represents a mechanism of deboronation.

摘要

硼替佐米(1)是一种强效的、同类首创的二肽基硼酸蛋白酶体抑制剂,用于治疗复发的多发性骨髓瘤患者,这类患者的疾病对传统治疗方案具有难治性。1的效力主要归因于硼酸部分的存在,该部分适合与蛋白酶体的活性位点N端苏氨酸残基形成四面体中间体。因此,1的脱硼作用代表了这种化疗药物的失活途径。1的脱硼作用产生了非对映体甲醇酰胺代谢物(M1/M2)的近乎等量混合物,并且是在人体中观察到的主要代谢途径。来自人肝微粒体和人cDNA表达的细胞色素P450酶(P450)的体外结果表明P450在1的脱硼作用中发挥作用。在受控气氛下使用18O标记的氧证实了P450介导的1脱硼作用中的氧化机制,因为在M1和M2中都发现了18O的掺入。化学产生的活性氧(ROS),例如在P450催化过程中作为副产物产生的那些,也被发现可使1脱硼,从而导致M1和M2的形成。已知P450 2E1能有效进行氧化还原循环,发现它可催化1脱硼,主要生成甲醇酰胺代谢物M1和M2,以及一对过氧甲醇酰胺,即2和3。超氧化物歧化酶(SOD)和过氧化氢酶的存在可防止1脱硼,因此,支持了ROS参与P450 2E1催化的脱硼反应。SOD和过氧化氢酶的存在也能保护1免受P450 3A4催化的脱硼作用,尽管程度较小。在P450 3A4反应中观察到的剩余脱硼活性可能表明涉及先前描述的P450更传统的活化酶氧化剂。我们目前的研究结果表明,P450的氧化酶活性(即ROS的形成)代表了一种脱硼机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验